FR2975600B1 - Agents pour le traitement de tumeurs - Google Patents

Agents pour le traitement de tumeurs

Info

Publication number
FR2975600B1
FR2975600B1 FR1154531A FR1154531A FR2975600B1 FR 2975600 B1 FR2975600 B1 FR 2975600B1 FR 1154531 A FR1154531 A FR 1154531A FR 1154531 A FR1154531 A FR 1154531A FR 2975600 B1 FR2975600 B1 FR 2975600B1
Authority
FR
France
Prior art keywords
treatment
tumors
agents
tumour
trl9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1154531A
Other languages
English (en)
Other versions
FR2975600A1 (fr
Inventor
Antoine Carpentier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNIVERSITE PARIS 13, FR
Assistance Publique Hopitaux de Paris (APHP)
Original Assignee
Assistance Publique Hopitaux de Paris (APHP)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris (APHP) filed Critical Assistance Publique Hopitaux de Paris (APHP)
Priority to FR1154531A priority Critical patent/FR2975600B1/fr
Publication of FR2975600A1 publication Critical patent/FR2975600A1/fr
Application granted granted Critical
Publication of FR2975600B1 publication Critical patent/FR2975600B1/fr
Application status is Expired - Fee Related legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
FR1154531A 2011-05-24 2011-05-24 Agents pour le traitement de tumeurs Expired - Fee Related FR2975600B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1154531A FR2975600B1 (fr) 2011-05-24 2011-05-24 Agents pour le traitement de tumeurs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1154531A FR2975600B1 (fr) 2011-05-24 2011-05-24 Agents pour le traitement de tumeurs
PCT/EP2012/059744 WO2012160153A1 (fr) 2011-05-24 2012-05-24 Agents pour le traitement de tumeurs
EP12723201.5A EP2714078A1 (fr) 2011-05-24 2012-05-24 Agents pour le traitement de tumeurs
US14/119,657 US20140120088A1 (en) 2011-05-24 2012-05-24 Agents for the treatment of tumors

Publications (2)

Publication Number Publication Date
FR2975600A1 FR2975600A1 (fr) 2012-11-30
FR2975600B1 true FR2975600B1 (fr) 2013-07-05

Family

ID=46148883

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1154531A Expired - Fee Related FR2975600B1 (fr) 2011-05-24 2011-05-24 Agents pour le traitement de tumeurs

Country Status (4)

Country Link
US (1) US20140120088A1 (fr)
EP (1) EP2714078A1 (fr)
FR (1) FR2975600B1 (fr)
WO (1) WO2012160153A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
SG10201403841QA (en) 2009-07-06 2014-09-26 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 官能化核酸の合成のための方法
CN104684893B (zh) 2012-07-13 2016-10-26 日本波涛生命科学公司 不对称辅助基团
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
AR095882A1 (es) * 2013-04-22 2015-11-18 F Hoffmann-La Roche Ag Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
US10322173B2 (en) * 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
AU2015207773A1 (en) 2014-01-16 2016-08-04 Wave Life Sciences Ltd. Chiral design
US20190134190A1 (en) * 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
WO1996002555A1 (fr) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040006034A1 (en) 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
AU2788901A (en) 2000-01-14 2001-07-24 Us Health Oligodeoxynucleotide and its use to induce an immune response
JP4443810B2 (ja) 2000-01-26 2010-03-31 イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG誘導性免疫刺激の調節
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AU7529401A (en) 2000-06-07 2001-12-17 Biosynexus Inc Immunostimulatory rna/dna hybrid molecules
EP1322656B1 (fr) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation de l'activite immunostimulatrice d'analogues oligonucleotidiques immunostimulateurs par des modifications chimiques de position
EP1985702A3 (fr) * 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH Acides nucléiques de type CPG et leurs procédés d'utilisation
CA2451974C (fr) 2001-06-21 2014-10-14 Karen L. Fearon Composes immunomodulateurs chimeriques et leurs procedes d'utilisation
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP1412390A2 (fr) 2001-07-26 2004-04-28 Tanox, Inc. Agents pouvant activer ou inhiber le recepteur 9 de type toll
CA2388049A1 (fr) 2002-05-30 2003-11-30 Immunotech S.A. Oligonucleotides immunostimulateurs et utilisations connexes
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
KR20060012622A (ko) 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
AU2005266225A1 (en) * 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
WO2007059041A2 (fr) * 2005-11-11 2007-05-24 Pfizer, Inc. Combinaisons et methodes d'utilisation d'un oligonucleotide immunomodulatoire
US8034905B2 (en) * 2007-11-09 2011-10-11 Affitech Research, AS Anti-VEGF antibody compositions and methods
WO2009155332A1 (fr) * 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Ligands de récepteurs de type toll utilisés comme adjuvants à une vaccinothérapie pour les tumeurs cérébrales
TWI432436B (zh) * 2008-12-09 2014-04-01 Gilead Sciences Inc 類鐸受體的調節劑
CA2999345A1 (fr) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Procedes de traitement d'un cancer et d'etats non neoplasique
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System

Also Published As

Publication number Publication date
US20140120088A1 (en) 2014-05-01
EP2714078A1 (fr) 2014-04-09
FR2975600A1 (fr) 2012-11-30
WO2012160153A1 (fr) 2012-11-29

Similar Documents

Publication Publication Date Title
DK2683384T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
BR112015003815A2 (pt) métodos e composições para o tratamento de uma condição genética
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
RU2019101617A (ru) СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EP2964084A4 (fr) Facteurs de forme pour l'évaluation physiologique multimodale de santé du cerveau
HK1215374A1 (zh) 依魯替尼聯合療法
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
BR112015002536A2 (pt) métodos para produzir recipientes flexíveis.
RU2016145968A (ru) Улучшенные способы производства средств адоптивной клеточной терапии
BR112015032031A2 (pt) métodos e processos para avaliação não invasiva das variações genéticas
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
BR112014004387A2 (pt) aparelho de tratamento de vestuário
MX2014005139A (es) Protocolo de tratamiento de la diabetes tipo 2.
PH12014501844B1 (en) Peptidomimetic macrocycles
BR112015007494A2 (pt) aparelho para tratamento dentário.
SG11201400616YA (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EP2834943A4 (fr) Base de données de hachage cryptographique
EP2737445A4 (fr) Recommandations ayant un rapport avec un produit social
EA201270722A1 (ru) Формы рифаксимина и их применение
BR112016007401A2 (pt) métodos e processos para avaliação não invasiva das variações genéticas
BR112014027478A2 (pt) métodos de processamento de materiais lingnocelulósicos".
EA201591166A1 (ru) Ингибиторы аутотаксина
BR112014032105A2 (pt) método para o tratamento de câncer

Legal Events

Date Code Title Description
TQ Partial transmission of property

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Effective date: 20130305

Owner name: UNIVERSITE PARIS 13, FR

Effective date: 20130305

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20180131